All In Biotech

Drug Trial Radar · NCT00160173

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

Efficacy Study Comparing 0.9 g and 1.25 g EstroGel® 0.03% Doses With Placebo in the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Associated With Menopause

Last checked: Nov 20, 2026Latest source record: Sep 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 221 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

221

Actual

Start

Dec 2, 2004

Primary completion

Sep 6, 2005

Study completion Sep 6, 2005

Sponsor

Lead sponsor
ASCEND TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Solvay Pharmaceuticals
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 45 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.

Conditions

  • Postmenopausal Symptoms

Interventions

  • EstrogelDrug

  • PlaceboOther

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

109 sites in 1 country. Site status is shown where the registry gives one.

  • Site 112

    Birmingham, Alabama

  • Site 74

    Mobile, Alabama

  • Site 20

    Montgomery, Alabama

  • Site 34

    Tucson, Arizona

  • Site 68

    Tucson, Arizona

  • Site 5

    Jonesboro, Arkansas

  • Site 88

    Little Rock, Arkansas

  • Site 95

    Little Rock, Arkansas

  • Site 104

    Carmichael, California

  • Site 42

    Encinitas, California

  • Site 21

    San Diego, California

  • Site 37

    San Diego, California

  • Site 78

    San Diego, California

  • Site 82

    San Diego, California

  • Site 69

    Avon, Connecticut

  • Site 58

    Bridgeport, Connecticut

  • Site 3

    Groton, Connecticut

  • Site 72

    Hartford, Connecticut

  • Site 54

    New Britain, Connecticut

  • Site 79

    Southport, Connecticut

  • Site 18

    Waterbury, Connecticut

  • Site 97

    West Hartford, Connecticut

  • Site 35

    Aventura, Florida

  • Site 36

    Aventura, Florida

  • Site 105

    Clearwater, Florida

  • Site 49

    Clearwater, Florida

  • Site 91

    Daytona Beach, Florida

  • Site 57

    Melbourne, Florida

  • Site 109

    Miami, Florida

  • Site 39

    Pinellas Park, Florida

  • Site 107

    Spring Hill, Florida

  • Site 100

    Tampa, Florida

  • Site 77

    West Palm Beach, Florida

  • Site 61

    Alpharetta, Georgia

  • Site 81

    Alpharetta, Georgia

  • Site 28

    Atlanta, Georgia

  • Site 93

    Atlanta, Georgia

  • Site 55

    Decatur, Georgia

  • Site 13

    Douglasville, Georgia

  • Site 87

    Powder Springs, Georgia

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.